James Tait, Simon Erridge, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Jonathan Hoare, Shaheen Khan, Mark Weatherall, James J Rucker, Michael Platt, Mikael H Sodergren
BACKGROUND: The following study evaluated the clinical outcomes of patients enrolled in the UK Medical Cannabis Registry, who were treated with inhaled dried flower (Adven® EMT2, Curaleaf International, Guernsey), and sublingual/oral medium-chain triglyceride-based oils (Adven, Curaleaf International, Guernsey) for chronic pain. METHODS: In this cohort study, the primary outcomes were changes in validated patient reported outcome measures (PROMs) at 1, 3, and 6 months compared to baseline, and adverse event analysis...
April 6, 2023: Expert Review of Neurotherapeutics